Had the pleasure of attending this event today. Summary below.
The University of Chicago Innovation Fund (IF) is excited to announce the Fall 2017 investment cycle. Applicants from across the University of Chicago, Argonne National Lab, Fermilab, and the Marine Biology Laboratory will compete for up to $250,000 in proof-of-concept capital. Previous finalists have built exciting technologies across a wide range of industries representative of the core strengths of the University and our partners.
Finalist teams include:
- Immunarits is a biotech startup formed by UChicago scientists to develop immune-therapeutics targeting Staph Aureus. Staphylococcus aureus and its antibiotic-resistant MRSA strains, is the most frequent cause of infectious disease morbidity and mortality in the United States and beyond.
- Onchilles is developing a novel biologic for the treatment of cancer, which has several exciting properties. It kills human cancer cells irrespective of their genetic makeup and anatomical location; it is not toxic to normal human cells; and it shrinks tumors within days and induces anti-tumor immunity in pre-clinical models.
- Oxalo Therapeutics is developing a first-in-class drug therapy derived from a gut bacterium to prevent and treat kidney stone disease. The Oxalo Therapeutics team leverages its expertise in nephrology, microbiome research, and biotech ventures to arrive at solutions for treatment and prevention of kidney diseases such as hyperoxaluria and oxalate-based kidney stones.
- Gaps in Service has developed a software-as-a-service platform that connects hospitals with partnering clinics to improve specialty care access for patients who need it. By making it easier for non-integrated health systems to connect, share information, schedule patients, and assess quality, the Gaps in Service platform achieves the twin goals of improving health outcomes in underserved communities and boosting productivity and utilization of specialty services.
All four Innovation Fund finalists are based on University technology and are being supported by the Polsky Center.
Please join us for the final pitches of these fantastic teams to the Innovation Fund Advisory Committee, an esteemed group of judges made up of investors, serial entrepreneurs and industry experts. As a member of the Chicago innovation community, the Fund team would be honored to have you attend.